Subject(s)
Eyelid Neoplasms , Sebaceous Gland Neoplasms , Female , Humans , Male , Middle Aged , Adenocarcinoma, Sebaceous/diagnosis , Adenocarcinoma, Sebaceous/chemically induced , Adenocarcinoma, Sebaceous/drug therapy , Eyelid Neoplasms/drug therapy , Eyelid Neoplasms/diagnosis , Sebaceous Gland Neoplasms/diagnosis , Sebaceous Gland Neoplasms/chemically induced , Sebaceous Gland Neoplasms/drug therapy , AdultABSTRACT
There are sparse data on neoadjuvant systemic chemotherapy (NACT) in eyelid sebaceous gland carcinoma (SGC). The aim of this study was to evaluate efficacy and outcomes with NACT in eyelid SGC. We retrospectively analyzed 8 patients who received platinum-based NACT. The median number of cycles per patient was 4 (range, 3-5). The mean percentage reduction of tumor diameter after NACT was 71% (range, 30-100%). Two patients had a radiological complete response (CR). After NACT, surgical treatment for residual tumor was performed in 5 cases. One patient had a pathological CR and is recurrence free for 11 years. After a mean follow-up period of 44.5 months (range, 9-109), tumor recurrence occurred in 4 cases. Among these 4 cases, 3 were rechallenged with the same regimen and all responded. Systemic NACT has a role in eyelid SGC, downstages the tumor, and allows less aggressive and organ-sparing surgeries, warranting a prospective study.
